Loading company
Stereotaxis, Inc.
STXS · NYSE · ·
Next earnings: November 10, 2026
$1.27+1.2%Sep 29 close
- 1M
- -12.8%
- 6M
- -28.9%
- 1Y
- -59.3%
- 5Y
- -78.5%
STXS · NYSE · ·
Next earnings: November 10, 2026
$1.27+1.2%Sep 29 close
Stereotaxis, Inc. is scheduled to report next on November 10, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $7.7M | $8.8M | -12.82% |
| Profit | -$4.5M | -$3.8M | -16.78% |
| Profit per share | -$0.05 | -$0.05 | 0.00% |
| Free Cash Flow | -$3.7M | $1.3M | -395.81% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Stereotaxis has reached an important commercial inflection point. Following years of product development and regulatory milestones, the Company’s expanded robotic platform is now generating accelerating commercial adoption across multiple product lines,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Stereotaxis, Inc.’s Item 2.02 8-K filed August 11, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Stereotaxis, Inc. has no earnings call transcript available.